8-K: BioSig Technologies Enters $5 Million Equity Subscription Agreement with Lind Global Fund III, LP

BioSig Technologies secures a $5 million equity line with Lind Global Fund III, LP, providing the company with the option to sell shares over the next 36 months.

Summary

• BioSig Technologies, Inc. has entered into an Equity Subscription Agreement with Lind Global Fund III, LP, effective February 28, 2025.
• The agreement allows BioSig to sell up to $5.0 million of its common stock to Lind Global over a 36-month period.
• BioSig has the right, but not the obligation, to initiate these sales, known as Advances.
• The price per share for each Advance will be 95% of the lowest daily VWAPs during a five-day trading period after BioSig notifies Lind Global of its intent to sell shares.
• BioSig will control the timing and amount of any sales of Common Stock to the Investor.
• The maximum number of shares the company may require the Investor to purchase in any Advance is an number equal to 66.667% of the average daily volume of the Common Stock on the Nasdaq Stock Market during the five consecutive trading days immediately preceding the date of the Advance Notice.
• As consideration for Lind Global's commitment, BioSig will issue 108,542 shares of common stock to the investor.
• BioSig had previously advanced to the Investor $10,000 to cover certain expenses related to the Subscription Agreement.
• The agreement includes a cap on the number of shares that can be issued to Lind Global without stockholder approval, set at 19.99% of the outstanding shares immediately prior to the agreement, or 4,605,765 shares, unless the average price of all sales equals or exceeds $0.88 per share.
• Lind Global's ownership is capped at 4.99% of BioSig's outstanding shares, which can be increased to 9.99% with 61 days' notice to the company.
• The agreement is contingent upon BioSig filing a registration statement with the SEC to register the shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The agreement provides BioSig with access to capital, but also introduces potential dilution for existing shareholders. The terms are fairly standard for this type of financing.

Positives

• BioSig gains access to a $5 million equity line, providing potential funding for its business and operations.
• BioSig retains control over the timing and amount of share sales to Lind Global.
• The agreement allows BioSig to specify a minimum acceptable price per share in each Advance.
• The agreement does not obligate BioSig to sell any shares, providing flexibility in managing its funding needs.

Negatives

• The share price for Advances is set at 95% of the lowest daily VWAPs during a five-day trading period, which could result in dilution for existing shareholders.
• The issuance of 108,542 commitment shares to Lind Global will immediately dilute existing shareholders.
• There is no guarantee that BioSig will be able to sell any shares or receive any proceeds under the agreement.
• The agreement includes a cap on the number of shares that can be issued to Lind Global without stockholder approval, set at 19.99% of the outstanding shares immediately prior to the agreement, or 4,605,765 shares, unless the average price of all sales equals or exceeds $0.88 per share.

Risks

• Actual sales of common stock to the investor will depend on a variety of factors to be determined by the company and its management from time to time, which may include, among other things, market conditions, the trading price of the common stock and determinations by the company and its management as to the appropriate sources of funding for the company's business and operations.
• There can be no assurance that the company will sell any shares of common stock or receive any proceeds therefrom under the subscription agreement.
• The company may need to seek stockholder approval to issue shares in excess of the Exchange Cap, and there is no guarantee that such approval will be obtained.
• The investor's obligation to purchase shares is subject to conditions, including the effectiveness of a registration statement, which could delay or prevent funding.

Future Outlook

BioSig intends to use the proceeds from the sale of Advance Shares for general corporate purposes, as will be detailed in a future prospectus.

Industry Context

This type of financing agreement is relatively common for small-cap companies seeking flexible access to capital. It allows them to raise funds as needed, but also carries the risk of dilution for existing shareholders.

Comparison to Industry Standards

• Similar agreements are often seen with companies like Diffusion Pharmaceuticals and Evofem Biosciences, which have utilized equity lines to fund ongoing research and development.
• The terms, including the discount to VWAP and the commitment fee, are generally in line with industry standards for this type of financing, although the specific percentages can vary based on the company's financial health and market conditions.
• The 19.99% Exchange Cap is a standard provision to avoid requiring immediate shareholder approval, similar to what is seen in other Nasdaq-listed companies.

Stakeholder Impact

• Shareholders may experience dilution if BioSig sells shares to Lind Global at a discount to the market price.
• The agreement provides BioSig with financial flexibility, which could benefit employees and other stakeholders.
• The agreement could impact the company's ability to meet its financial obligations.

Next Steps

• BioSig must file a registration statement with the SEC to register the shares for resale.
• BioSig may choose to draw down on the equity line by issuing Advance Notices to Lind Global.
• BioSig may seek stockholder approval to issue shares in excess of the Exchange Cap.

Key Dates